AI agents transform every phase of this journey: from initial molecular research to post-market surveillance.
Drug discovery, clinical trials, and pharmacovigilance
- Molecular screening: analyzing millions of compounds for therapeutic potential
- Binding affinity prediction for target-molecule interactions
- ADMET profiling: predicting absorption, distribution, metabolism, excretion, and toxicity
- Patient identification: EHR analysis for trial eligibility based on protocol criteria
- Protocol adherence monitoring: flagging deviations and adverse events in real-time
- Pharmacovigilance: detecting safety signals from spontaneous reports, literature, and real-world data
Regulatory submissions and post-market surveillance
After market introduction, AI agents continuously monitor adverse event reports from multiple sources. They detect safety signals early, automatically generate Individual Case Safety Reports (ICSRs) compliant with EMA and FDA requirements, and ensure all regulatory submissions are timely and complete.
Match-AI works with pharmaceutical companies and CROs to implement AI agents that accelerate drug discovery, automate trial documentation, and ensure regulatory compliance.
Written by
Chris de Graaf
Co-owner
Has a background in commerce and conversion. At Match-AI, he helps companies turn meetings and leads into concrete, automated follow-up.
Follow on LinkedIn
